Concurrent chemo-radiotherapy(CCRT) with concomitant boost radiotherapy(CBRT) in locally advanced head and neck cancers.

long term results comparing concurrent chemoradiotherapy with concomitant boost radiotherapy in locally addvanced head and neck cancer.

Status

Active, not recruiting

Phases

Phase 4

Study type

Observational

Source

CTRI

Registry ID

CTRI/2021/06/034087

Enrollment

100

Registered

2021-06-08

Start date

Unknown

Completion date

Unknown

Last updated

2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: C139- Malignant neoplasm of hypopharynx,unspecified Health Condition 2: C109- Malignant neoplasm of oropharynx,unspecified

Interventions

Intervention1: concurrent chemo-radiotherapy,concomitant boost radiotherapy: Study arm (CBRT arm): In CBRT arm, dose of 45 Gy/25 fractions/5 weeks as phase I was given to the primary tumour and the dr

Eligibility

Inclusion criteria

Inclusion criteria: Histology â?? squamous cell carcinoma.17 • Stage III, IV A and IV B. • Previously untreated patients. • Hb > 10gm%. • Pre-treated leucocyte count of > 4000/cu mm. • Platelet count > 100,000/cu mm. • Normal renal and liver function tests. • Karnofsky performance status Î±Î±>= 70.

Exclusion criteria

Exclusion criteria: • Histology other than squamous cell carcinoma. • Sites other than oropharynx, hypopharynx, and larynx. • Age > 70yrs. • Deranged RFT / LFT. • Previous treatment with RT/ Chemotherapy. • Any prior/ synchronous malignancy. • Hypersensitivity to platinum agents. • Lymph nodes extending behind the spinal cord. • Karnofsky performance status • Distant metastasis

Design outcomes

Primary

Measure	Time frame
To compare the efficacy of concomitant boost radiotherapy against concurrent chemoradiation in locally advanced head and neck cancer (Oropharynx/Larynx/Hypopharynx). â?¢ To find out the tolerability and toxicity profile of concomitant boost radiotherapy over concurrent chemoradiation in locally advanced head and neck cancer.Timepoint: 6 weeks	—

Secondary

Measure	Time frame
overall survival and disease free survivalTimepoint: 2 years	—

Countries

India

Contacts

Public ContactShabnum Thakur

IGMC Shimla

thakurshabnum7@gmail.com9459830966

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026